Camurus: License Agreement with Lilly - Redeye
Bildkälla: Stockfoto

Camurus: License Agreement with Lilly - Redeye

Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as strong validation of its FluidCrystal platform.

Börsvärldens nyhetsbrev